1. Home
  2. BRUN vs OMER Comparison

BRUN vs OMER Comparison

Compare BRUN & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boost Run Inc. Class A Common Stock

BRUN

Boost Run Inc. Class A Common Stock

N/A

Current Price

$6.12

Market Cap

1.4B

Sector

Technology

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$16.93

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BRUN
OMER
Founded
2023
1994
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2026
2008

Fundamental Metrics

Financial Performance
Metric
BRUN
OMER
Price
$6.12
$16.93
Analyst Decision
Strong Buy
Buy
Analyst Count
4
3
Target Price
★ $42.75
$27.50
AVG Volume (30 Days)
★ 4.0M
1.1M
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 98.15
EPS
N/A
★ 0.77
Revenue
N/A
★ $29,868,000.00
Revenue This Year
$550.82
N/A
Revenue Next Year
$214.84
$73.59
P/E Ratio
★ N/A
$23.61
Revenue Growth
★ N/A
N/A
52 Week Low
$6.62
$6.24
52 Week High
$40.46
$21.24

Technical Indicators

Market Signals
Indicator
BRUN
OMER
Relative Strength Index (RSI) 32.25 43.25
Support Level N/A $16.17
Resistance Level $26.68 $19.68
Average True Range (ATR) 0.82 0.83
MACD 0.05 -0.01
Stochastic Oscillator 17.89 23.34

Price Performance

Historical Comparison
BRUN
OMER

About BRUN Boost Run Inc. Class A Common Stock

Boost Run Inc is an NVIDIA Cloud Provider. Its platform provides GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. Enterprises rely on Boost Run to power their main demanding AI workloads with the performance, security, and reliability their operations require. The group maintains SOC 2 Type II, HIPAA, ISO 27001, and ISO 27701 certifications at the operator level, and partners with data center facilities that uphold equivalent security and compliance standards.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: